干预COVID-19相关的超水性状态,以循环血栓形成为特征,利用直接血栓抑制剂进行干预
Madhav Seshadri1, Jasimuddin Ahamed1,2, Jeffrey Laurence1
1Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY, USA.
Thrombosis update
|April 15, 2024
概括
在COVID-19患者的连续置换疗法 (CRRT) 中,经常会出现电路血栓形成. 阿尔加特罗班是一种直接的血栓激素抑制剂,在肝素失败时有效地解决了血栓形成,这表明高纤维素和低抗血栓激素III水平的作用.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 关键护理医学 关键护理医学
- 血液学 血液学 血液学
背景情况:
- 循环血栓是连续脏替代疗法 (CRRT) 的重要并发症.
- 标准的基于肝素的抗凝药在预防COVID-19患者的CRRT电路血栓形成方面经常是无效的.
研究的目的:
- 为了研究阿斯拉夫罗班在治疗COVID-19患者CRRT电路血栓的疗效.
- 探索反映该患者群体抗凝血反应的潜在生物标志物.
主要方法:
- 五名COVID-19患者经历CRRT电路血栓形成的回顾性病例系列.
- 患者在失败的基于氨酸的抗凝药后,接受了直接的血栓抑制剂阿斯拉夫罗班.
- 监测纤维素和D-二聚合物水平以评估抗凝血反应.
主要成果:
- 尽管先前的肝素失败,阿尔加特罗班在所有五个病例中都成功解决了电路血栓.
- 纤维素水平的变化与抗凝血反应的相关性比D-二聚合物水平更好.
- 在这些患者中观察到纤维素因子升高和抗血素III活性降低.
结论:
- 阿尔加特罗班为管理COVID-19患者的CRRT电路血栓形成提供了可行的替代方案,这些患者对肝素不耐药.
- 在这种情况下,纤维素水平可能会比D-二次体更可靠地表明抗凝血功效.
- 底层的高凝血状态,以高纤维素和低抗血栓III为特征,可能解释了 argatroban 的优势.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
689
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
689
01:20Extrinsic and Intrinsic Pathways of Hemostasis
7.4K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.4K
01:16Clot Retraction and Fibrinolysis
5.7K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.7K
01:24Disorders of Hemostasis
881
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
881
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
522
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
522
01:09Coagulation
6.4K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.4K